Deal could put FDA reps in China

Share this article:

A deal between the US and China could mean more FDA inspection of manufacturing plants. Regulatory Focus reports that the countries struck a deal Dec. 5 that officials say will mean “a substantial increase in the number of US food and drug inspectors” on site.

The news could mean a new rash of Warning Letters to read up on: RF notes that on-site inspections in India, for example, netted six Warning Letters in 2012, and inspectors also put a dent in businesses including Wockhardt and Fresenius Kabi, after finding problems with their facilities.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.